PRODUKT OBJĘTY BADANIEM: MUCOSAMIN SPRAY
Oral Mucositis in patients undergoing haematopoietic stem cell transplants HSCT
Study:

Assess the efficacy of Mucosamin Spray for the treatment of oral mucositis in patients undergoing haematopoietic stem cell transplants (HSCT). Oral Mucositis may occur in up to 100% of patients undergoing condition regimen to HSCT

Design:

68 patients were divided in 2 groups:

  • Mucosamin group (34 patients): all received a complete session of professional oral health care (POHC) and Mucosamin spray on mucositis lesions 3-4 times a day after a meal
  • Control group (34 patients): received only Clorexidine 0.20% on oral mucositis lesions
Measurements:

Mucosamin group after complete session of professional oral hygiene:

  • O’Leary Index Placque (Placque Control Record)
  • Bleeding Index
  • Periodontal Screening and Recording Index (PSR)
Evaluation of gravity of oral mucositis

Evaluation of gravity of oral mucositis between patients treated with Mucosamin who had POHC compared to patients treated only with clorexidine 0.20%
Light Mucositis: WHO grade 1 and 2; Severe Mucositis: WHO grade 3 and 4

Wyniki kliniczne

  • Treated patients with Mucosamin Spray developed less severe mucositis.
  • Treated patients with Mucosamin Spray resolved the mucositis in less time.
  • Maximum pain, measured with VAS scale, was lower in patients treated with Mucosamin Spray.

Ruggiero T. et al.
Journal of Biological Regulators & Homeostatic Agents
Vol. 30, no. 3, 889-894
2016

Skontaktuj się z przedstawicielem aby otrzymać ofertę dla specjalistów
TO JEST WYRÓB MEDYCZNY. UŻYWAJ GO ZGODNIE Z INSTRUKCJĄ UŻYWANIA LUB ETYKIETĄ.